USP and FDA Look to Improve Drug Packaging Standards
This article was originally published in The Gold Sheet
Executive Summary
FDA and the U.S. Pharmacopeia are looking to improve their standards for drug packaging systems. USP is proposing new test methods for detecting contaminants in plastic packaging systems and has proposed a best practice guide for assessing extractables and leachables, while FDA has announced plans to update its 1999 container closure guidance.
You may also be interested in...
Drug Makers Urged To Collect Own Excipient Metals Data To Comply With ICH Q3D
While leveraging published data may help pharmaceutical manufacturers understand the general risks of using excipients with known elemental impurities, it is less helpful in understanding specific risks.
Heat Treat Wooden Pallets to Avoid Taint of TBP, Drug Makers Told
Pharmaceutical manufacturers should use only heat-treated wooden pallets to ensure that they don’t have TBP-taints that can cause musty and moldy odors in plastic medicine bottles. There have been eight drug recall incidents since 2009 for smells emanating from TBP.
Glass Quality Crisis Prompts Multi-Faceted Array of Risk-Based Improvements
Drug makers, glass suppliers and FDA officials who attended a recent Parenteral Drug Association glass quality conference made some progress toward understanding why glass-related recalls have surged and what corrective and preventive measures they should apply.